NOAEL Studies
Cosmetic Ingredient
Hydroxyanthraquinoneaminopropyl Methyl Morpholinium Methosulfate NOAEL Studies
INCI: HYDROXYANTHRAQUINONEAMINOPROPYL METHYL MORPHOLINIUM METHOSULFATE
CAS: 38866-20-5
Raw No Observed Adverse Effect Level endpoint records grouped by source. This page does not render calculated Margin of Safety values.
COSMOS DB 2 endpoints
| Source | Endpoint Type | Value | Unit | Species | Route | Duration | Study Type | Reference |
|---|---|---|---|---|---|---|---|---|
| COSMOS DB | LOAEL | 200 | mg/kg bw/day | rat | oral | 90 day | Subchronic | SCCP; C. Fabreguettes. 13-Week Toxicity Studyby Oral Route in Rats. CIT Study No. 12417TCR (95/2/002), November 6, 1995 |
| COSMOS DB | NOAEL | 50 | mg/kg bw/day | rat | oral | 90 day | Subchronic | SCCP; C. Fabreguettes. 13-Week Toxicity Studyby Oral Route in Rats. CIT Study No. 12417TCR (95/2/002), November 6, 1995 |
SCCS Opinion 7 endpoints
| Source | Endpoint Type | Value | Unit | Species | Route | Duration | Study Type | Reference |
|---|---|---|---|---|---|---|---|---|
| SCCS Opinion | NOAEL | =0.015 | mg/kg bw/d | rat | oral | 13-week | dermal absorption | p.28 |
| SCCS Opinion | NOAEL | =26 | mg/kg bw/d | human | - | - | NOAEL study | p.27 |
| SCCS Opinion | NOAEL | =50 | mg/kg bw/d | - | - | Chronic | genotoxicity | p.17 |
| SCCS Opinion | NOAEL | =87.5 | % | rat | oral | 13 week | dermal absorption | p.19 |
| SCCS Opinion | NOAEL | =200 | mg/kg bw/d | - | - | Chronic | genotoxicity | p.14 |
| SCCS Opinion | NOAEL | =200 | mg/kg | rat | oral | 13 week | dermal absorption | p.19 |
| SCCS Opinion | NOAEL | =800 | mg/kg bw/d | human | - | - | NOAEL study | p.18 |
Regulatory source 10 endpoints
| Source | Endpoint Type | Value | Unit | Species | Route | Duration | Study Type | Reference |
|---|---|---|---|---|---|---|---|---|
| Regulatory source | - | 26 | mg/kg bw/d | human | - | - | - | p.27 |
| Regulatory source | - | 800 | mg/kg bw/d | human | - | - | - | p.18 |
| Regulatory source | dermal absorption | =0.015 | mg/kg bw/d | rat | oral | 13-week | dermal absorption | p.28 |
| Regulatory source | dermal absorption | =50 | mg/kg bw/d | rat | oral | 13-week | dermal absorption | p.28 |
| Regulatory source | dermal absorption | 87.5 | % | rat | oral | 13 week | dermal absorption | p.19 |
| Regulatory source | dermal absorption | =200 | mg/kg | rat | oral | 13 week | dermal absorption | p.19 |
| Regulatory source | genotoxicity | 50 | mg/kg bw/d | - | - | Chronic | genotoxicity | p.17 |
| Regulatory source | genotoxicity | 200 | mg/kg bw/d | - | - | Chronic | genotoxicity | p.14 |
| Regulatory source | repeated dose toxicity | 50 | mg/kg bw/d | rat | oral | 13 week | repeated dose toxicity | p.28 |
| Regulatory source | repeated dose toxicity | 200 | mg/kg bw/d | rat | oral | 13 week | repeated dose toxicity | p.19 |
openFDA substances 1 endpoint
| Source | Endpoint Type | Value | Unit | Species | Route | Duration | Study Type | Reference |
|---|---|---|---|---|---|---|---|---|
| openFDA substances | FDA UNII substance identifier | RNJ1LHE5O7 | UNII | - | - | - | chemical | - |